Dr Reddy's Laboratories Ltd

DRREDDY

Overview

    • Equity Style Box

      Large Blend

    • Sector

      Healthcare

    • Industry

      Drug Manufacturers - Specialty & Generic

    • Day Range

      1,095.05 – 1,110.25

    • Year Range

      1,092.45 – 1,421.49

    • Market Cap

      923.0912 Bil

    • Volume / Avg

      1.3 Mil / 2.3 Mil

    • Price / Sales

      2.97

    • Price / Book

      2.92

    • Price / Earnings

      17.22

    • Forward Div Yield

      0.72%

    • Trailing Div Yield

      0.72%

Login To Show Full Chart

Summary

Fair Value Assessment
Fairly Valued
Fair ValueQ1,125.58UncertaintyLow
Close Price1,107.95Mar 14, 2025
Market Closed
₹ 1,107.95
Price Up by 2.80 | 0.25 %
Trading Information Business Description
Previous Close
1,107.95
Day Range
1,095.05 – 1,110.25
Year Range
1,092.45 – 1,421.49
Bid / Ask
1,107.95 × 1107.95
Market Cap
923.1 Bil
Volume / Average
1.3 Mil / 2.3 Mil
Beta (5-Year)
0.29
Shares Outstanding
833.15 Mil
Primary Exchange
National Stock Exchange of India

Business Description
Dr. Reddy’s is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy’s also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy’s has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy’s also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Contact
8-2-337, Road No. 3 Banjara Hills, Hyderabad, TG 500 034
T +91 4049002900
shares@drreddys.com opens in a new tab
www.drreddys.com opens in a new tab
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Dec 31, 2024
Fiscal Year End
Mar 31, 2025
Employees
27,048
As of Mar 31, 2024

Key Metrics

Income Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Revenue
311.31 279.16 245.88 214.39 189.72 174.60
Revenue Growth %
14.74% 13.54% 14.69% 13.00% 8.66% 13.49%
Gross Profit
184.65 163.61 139.34 113.84 103.08 94.01
Gross Profit Margin %
59.31% 58.61% 56.67% 53.10% 54.33% 53.84%
Operating Income
67.94 65.31 59.05 35.92 32.91 32.77
Operating Margin %
21.83% 23.39% 24.02% 16.75% 17.35% 18.77%
EBIT
72.75 71.30 60.62 32.29 26.56 18.13
EBIT Margin %
23.37% 25.54% 24.65% 15.06% 14.00% 10.38%
EBITDA
88.97 86.14 73.25 44.12 39.35 30.60
EBITDA Margin %
28.58% 30.86% 29.79% 20.58% 20.74% 17.53%
Net Income
53.68 55.68 45.07 23.57 17.24 19.50
Net Profit Margin %
17.49% 19.95% 18.33% 10.99% 9.09% 11.17%
Basic EPS
64.48 66.93 54.29 28.42 20.79 23.53
Diluted EPS
64.39 66.80 54.17 28.34 20.73 23.48
Normalized EPS
58.26 45.84 74.96 68.10 81.30 114.79
Total Dividends per Share
8.00 8.00 6.00 5.00 5.00 4.00
Balance Sheet (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Total Assets
481.06 387.52 321.85 292.83 265.49 232.24
Total Liabilities
159.49 106.97 90.86 102.30 92.43 77.25
Total Debt
51.09 20.02 13.47 33.85 30.31 22.10
Total Equity
321.57 280.55 230.99 190.53 173.06 154.99
Cash And Cash Equivalents
12.29 7.11 5.78 14.85 14.83 2.05
Working Capital
121.07 152.01 121.10 87.84 64.86 57.56
Shares Outstanding (Bil)
0.83 0.83 0.83 0.83 0.83 0.83
Book Value Per Share
379.49 335.13 276.05 227.65 207.09 185.50
Total Debt To Equity
0.16 0.07 0.06 0.18 0.18 0.14
Cash Flow Statement (in Bil, except ratios)
12/31/2024
03/2024
03/2023
03/2022
03/2021
03/2020
Cash From Operating Activities
35.95 45.43 58.88 28.11 35.70 29.84
Cash From Investing Activities
-56.13 -40.28 -41.37 -26.39 -22.66 -4.92
Cash From Financing Activities
25.75 -3.76 -26.86 -2.42 -0.30 -25.16
Capital Expenditures
49.59 27.44 18.87 19.05 12.56 6.12
Free Cash Flow
16.38 35.91 46.01 21.63 30.02 29.65
Change in Cash
5.57 1.39 -9.36 -0.70 12.75 -0.24

Profile

Name (Age)
5-Year Trend
2020
2021
2022
2023
2024
Erez Israeli (57) Chief Executive Officer
121,640,000 121,640,000 127,150,000 195,380,000 197,090,000
M. V. Ramana (56) Chief Executive Officer, Branded Markets, India and Emerging Countries
57,480,000 57,480,000 66,600,000 80,200,000 82,740,000
Patrick Aghanian (59) Chief Executive Officer, European Generics
32,050,000 32,050,000 72,920,000 91,630,000 63,090,000
Marc Kikuchi (55) Chief Executive Officer, North America Generics
68,760,000 68,760,000 77,930,000 112,490,000 53,480,000
Parag Agarwal (58) Chief Financial Officer
— — 55,710,000 65,160,000 64,660,000
M V Narasimham (55) Deputy Chief Financial Officer
— — — 47,200,000 48,820,000
Sanjay Sharma (56) Global Head of Manufacturing
45,430,000 45,430,000 44,370,000 61,420,000 66,050,000
Archana Bhaskar (57) Chief Human Resource Officer
47,890,000 47,890,000 50,370,000 63,420,000 65,210,000
Sushrut Kulkarni (54) Global Head of Integrated Product Development Organisation
— — — 48,350,000 55,630,000
Deepak Sapra (49) Global Head of Pharmaceutical Services and Active Ingredients
25,160,000 25,160,000 30,440,000 40,120,000 41,900,000
Phani Mitra B (45) Chief Information Officer — — — — — —
B Phanimitra (—) Chief Digital and Information Officer
— — — 15,130,000 —
G.V. V. Prasad (63) Co-Chairman of the Board and Managing Director
— — — 187,710,000 —
Jayanth Sridhar (53) Global Head of Biologics
— — — 34,590,000 —
Krishna Venkatesh (51) Global Head, Quality and Pharmacovigilance
— — — 6,150,000 —
Total Compensation for all Key Executives INR
398,410,000 398,410,000 525,490,000 1,048,950,000 738,670,000
Transaction History

Shares in Thousands
0 5 10 15 20 25 30 35 40
>
No Data Available
There is no available information for this investment.
Sep
2023
    • Buy
    • Acquisition
    • Option Exercise
    • Disposition
    • Sell
Transaction Detail
No Data Available
There is no available information for this investment.

Ownership

Name
% Total
Shares Held
% Total
Assets
Trend
Prev. 8 Qtrs
Change Amount
Change %
Date
Stewart Inv APAC Ldrs B GBP Acc 2.32 3.35 19,345,625
—
—
Jan 31, 2025
SBI Nifty 50 ETF 1.31 0.69 10,872,588
-72,779
0.66%
Feb 28, 2025
Parag Parikh Flexi Cap Reg Gr 1.19 1.26 9,911,843
2,523,602
34.16%
Feb 28, 2025
Vanguard Total Intl Stock Index Inv 0.93 0.02 7,732,610
—
—
Jan 31, 2025
ICICI Pru Value Discovery Gr 0.84 1.69 6,986,059
813,232
13.17%
Feb 28, 2025
Total (for Top 5) 6.58 54,848,725
3,264,055
More Ownership Data

STOCKS
MUTUAL FUNDS
ADITYABIRLAAXISBajajBANDHANBARODABNPBOICANARADSPEDELWEISSFRANKLINTEMPLETONGROWWHDFCHELIOSHSBCICICIIIFLINVESCOITIJMKOTAKLICMahindraManulifeMIRAEMOTILALNAVINipponNJOldBridgePGIMPPFASQUANTQUANTUMSAMCOSBISHRIRAMSUNDARAMTATATAURUSTrustUNIONUTIWhiteOakZERODHA
INSURANCE FUNDS
ABSLAEGONAGEASFEDERALAVIVABAJAJALLIANZBHARTIAXACANARAHSBCORIENTBANKEDELWEISSTOKIOEXIDEFUTUREGENERALIHDFCICICIPRUDENTIALINDIAFIRSTKOTAKMAHINDRALICMAXLIFEPNBMETLIFEPRAMERICARELIANCENIPPONSAHARASBISHRIRAMSTARUNIONDAI-ICHITATAAIA

About Us

Connect With Us

© Copyright 2025 Morningstar, Inc. All rights reserved.
Terms of Use    Privacy Policy
© Copyright 2025 Morningstar, Inc. All rights reserved. Please read our Terms of Use above. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
As of December 1st, 2023, the ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar/Sustainalytics accepts no responsibility or liability whatsoever for the actions of third parties in this respect.
Company: Morningstar India Private Limited; Regd. Office: 9th floor, Platinum Technopark, Plot No. 17/18, Sector 30A, Vashi, Navi Mumbai – 400705, Maharashtra, India; CIN: U72300MH2004PTC245103; Telephone No.: +91-22-61217100; Fax No.: +91-22-61217200; Contact: Morningstar India Help Desk (e-mail: helpdesk.in@morningstar.com) in case of queries or grievances.
Top